A5005327464- Radiopharmaceutical Chemistry and Applications
- Neuroendocrine Tumor Research Advances
- Neuroblastoma Research and Treatments
- Lung Cancer Research Studies
- Medical Imaging Techniques and Applications
- Glioma Diagnosis and Treatment
- Medical Imaging and Pathology Studies
- Radioactive element chemistry and processing
- Nuclear Physics and Applications
- Peptidase Inhibition and Analysis
- Thyroid Cancer Diagnosis and Treatment
- Chemical Synthesis and Characterization
- Prostate Cancer Treatment and Research
- Nuclear Materials and Properties
- Chemical Reactions and Isotopes
- Radiation Detection and Scintillator Technologies
- Chemical Synthesis and Analysis
- Thermal and Kinetic Analysis
- Neuropeptides and Animal Physiology
- Radioactive Decay and Measurement Techniques
- Metal-Organic Frameworks: Synthesis and Applications
- Thyroid Disorders and Treatments
- Tryptophan and brain disorders
- Particle accelerators and beam dynamics
- Boron Compounds in Chemistry
National Centre for Nuclear Research
2014-2023
Institute of Atomic Energy
2009-2012
Peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues is a treatment option for patients with disseminated neuroendocrine tumours (NET). A combination the high-energy 90Y beta emitter larger lesions and lower energy 177Lu smaller has been postulated in literature.The aim of study was to evaluate combined 90Y/177Lu-DOTATATE comparison 90Y-DOTATATE alone.Fifty NET were included prospectively divided into two groups: group (n=25) treated 90Y-DOTATATE, whereas B...
Glioblastoma multiforme (GBM), the most common malignant brain tumor, mainly manifests as a primary de novo and less frequently secondary glial neoplasm. GBM has been demonstrated to overexpress NK-1 receptor substance P can be used ligand for targeted therapy. Alpha emitters, e.g. 213Bi, that deposit their high energy within short range allow selective irradiation of tumor cells while sparing adjacent neuronal structures.Among 50 glioma patients different subtypes have date treated with...
Neuroendocrine tumours (NET) are a heterogeneous group of neoplasms diffuse neuroendocrine cells. Surgery is the main aim in treatment NETs, which becomes impossible case large or infiltration into other tissues and/or important blood vessels. Neoadjuvant therapy might be helpful decreasing NET size also, leading us to point where tumour, previously considered inoperable, operable. The study was assess usage peptide receptor radionuclide (PRRT) as neoadjuvant treatment, enabling surgical...
One of the concepts theranostics in nuclear medicine is peptide receptor radionuclide therapy (PRRT), whereby labeled somatostatin analogs are used for imaging and treating inoperable or disseminated neuroendocrine tumors (NET).
Glioblastoma is the most common and malignant primary brain tumour, with a poor prognosis. Introduction of new treatment options critically important. The study aimed to assess appropriateness escalation doses toxicity [225Ac]Ac-DOTA-SP therapy.A total 21 patients (age 43.0 ± 9.5 years), histologically confirmed recurrent or conversion glioblastoma grade 4 following standard therapy, have been included in study. One 2 intracavitary port-a-cath systems were stereotactically inserted. Patients...
The aim of this study was to describe the normal physiological distribution 68Ga-DOTA-TATE using SUV reflect density somatostatin receptors in various organ systems. Methods A total 250 patients (90 men and 160 women) were imaged on a Biograph 64 PET/CT TruePoint (Siemens Medical Solutions) 60 80 minutes after injection 120 200 MBq (3.2-5.4 mCi) 68Ga-DOTA-TATE. Visual assessment performed all studies multimodality workstation, sites increased uptake recorded. SUVmax also calculated for each...
Glutamate carboxypeptidase II (GCP), also known as prostate specific membrane antigen (PSMA) has been found to be expressed in glioma vasculature in-vitro studies. GCP expression can traced with the use of [68Ga]Ga-PSMA-11 PET/CT used routinely for cancer imaging. The aim this paper was analyze recurrent glial tumors vivo. 34 patients (pts.) aged 44.5 ± 10.3 years suspicion recurrence histologically confirmed grade III (6 pts.) and IV (28 were included study. All underwent contrast-enhanced...
Glioblastoma (GB) is the most malignant primary brain tumor. Therefore, introduction of new treatment options critically important. The aim this study was to assess local with α emitters [ 213 Bi]Bi-DOTA-substance P (SP) and 225 Ac]Ac-DOTA-SP.Treatment performed as salvage therapy in patients recurrent secondary GB. Bi]Bi-DOTA-SP injected activity 1.85 GBq per cycle used 20 (48.2 ± 11.8 years old) 9 (38.8 10.8 GB Ac]Ac-DOTA-SP 15 (45.1 9.9 6 (37.8 6.4 a dose escalation scheme (10, 20, 30...
The imaging of neuroendocrine tumors has become one the most significant areas in nuclear oncology. In an attempt to provide high-quality and possible sensitivity at a reduced cost, time, radiation dose, several <sup>99m</sup>Tc agents have been proposed. aim this initial study was compare tumor uptake biodistribution 2 new 6-hydrazinopyridine-3-carboxylic acid (HYNIC)–derivatized Tyr<sup>3</sup>-octreotide analogs, <sup>99m</sup>Tc-[HYNIC,Tyr<sup>3</sup>]octreotide (<sup>99m</sup>Tc-TOC)...
A variety of radiolabelled minigastrin analogues targeting the cholecystokinin 2 (CCK2) receptor were developed and compared in a concerted preclinical testing to select most promising radiotracer for diagnosis treatment medullary thyroid carcinoma (MTC). DOTA–DGlu–DGlu–DGlu–DGlu–DGlu–DGlu–Ala–Tyr–Gly–Trp–Met–Asp–Phe–NH2 (CP04) after labelling with 111In displayed excellent characteristics, such as high stability, affinity, specific persistent tumour uptake low kidney retention animal...
BACKGROUND: 44 Sc as a positron emitter can be an interesting alternative to 68 Ga (T ½ = 67.71 min) due its longer half-life 3.97 h). Moreover, the b– 47 used for therapy when attached same biomolecule vectors. DOTA chelating agent has been proven suitable radiolabelling of peptides recognising tumour cell receptors in vivo with M 3+ radiometals. DOTA-derivatized have successfully labelled 90 Y and 177 Lu therapy, PET imaging. However, published data on Sc-labelled DOTA-biomolecules...
Background:The aim of this initial study was to evaluate the clinical and radiological effectiveness radioembolization (RE) using 188 Re-Human Serum Albumin (HSA) microspheres in patients with advanced, progressive, unresectable primary or secondary liver cancers, not suitable any other form therapy. Material/Methods:Overall, we included 13 20 therapy sessions.Clinical responses were assessed at 6 weeks after therapy, then every 3 months.The objective response classified according Response...
The peptide receptor radionuclide therapy (PRRT) is a treatment option for patients with disseminated, inoperable G1 and G2 neuroendocrine tumours (NETs). study aims to evaluate the safety, efficacy, progression-free survival (PFS) of after retreatment (R-PRRT) re-retreatment (RR-PRRT) tandem isotopes [90Y]Y/[177Lu]Lu-DOTATATE. Material Methods. Out 99 treated NETs, 26 were included in repeated PRRT (with 5 undergoing re-repeated treatment) an initial positive response four cycles later...
Case presentation: a 75-year-old man with 10-year history of nodular goitre was referred for clinical evaluation. The ultrasound scan revealed enlarged thyroid right lobe almost fully filled heterogeneous nodule numerous calcifications. Fine-needle aspiration biopsy suggested medullary carcinoma (MTC). Before the surgery patient to nuclear medicine department and somatostatin receptor imaging (SRS; 68Ga-DOTATATE) PET/CT performed. demonstrated an increased uptake within mass. Subsequent...